These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Nanomedicine and drug delivery. Wei C; Wei W; Morris M; Kondo E; Gorbounov M; Tomalia DA Med Clin North Am; 2007 Sep; 91(5):863-70. PubMed ID: 17826106 [TBL] [Abstract][Full Text] [Related]
25. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications. Chakraborty S; Dhakshinamurthy GS; Misra SK J Biomed Mater Res A; 2017 Oct; 105(10):2906-2928. PubMed ID: 28643475 [TBL] [Abstract][Full Text] [Related]
26. Mitochondria: An intriguing target for killing tumour-initiating cells. Yan B; Dong L; Neuzil J Mitochondrion; 2016 Jan; 26():86-93. PubMed ID: 26702582 [TBL] [Abstract][Full Text] [Related]
27. Nanomaterials for targeted drug delivery to cancer stem cells. Orza A; Casciano D; Biris A Drug Metab Rev; 2014 May; 46(2):191-206. PubMed ID: 24697156 [TBL] [Abstract][Full Text] [Related]
28. Nanocarriers as an emerging platform for cancer therapy. Peer D; Karp JM; Hong S; Farokhzad OC; Margalit R; Langer R Nat Nanotechnol; 2007 Dec; 2(12):751-60. PubMed ID: 18654426 [TBL] [Abstract][Full Text] [Related]
29. Multimodal Nanomedicine Strategies for Targeting Cancer Cells as well as Cancer Stem Cell Signalling Mechanisms. Kanwar JR; Samarasinghe RM; Kamalapuram SK; Kanwar RK Mini Rev Med Chem; 2017; 17(18):1688-1695. PubMed ID: 26891936 [TBL] [Abstract][Full Text] [Related]
30. Targeting liposomal nanomedicine to cancer therapy. Zhong J; Dai LC Technol Cancer Res Treat; 2012 Oct; 11(5):475-81. PubMed ID: 22475065 [TBL] [Abstract][Full Text] [Related]
31. Nucleic acid-based therapeutics for glioblastoma. Shir A; Levitzki A; Wagner E; Klein S; Ogris M Anticancer Agents Med Chem; 2011 Oct; 11(8):693-9. PubMed ID: 21707501 [TBL] [Abstract][Full Text] [Related]
32. Surface-active liposomes for targeted cancer therapy. Sofou S Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032 [TBL] [Abstract][Full Text] [Related]
33. Nanoparticle and targeted systems for cancer therapy. Brannon-Peppas L; Blanchette JO Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294 [TBL] [Abstract][Full Text] [Related]
35. Cancer stem cells: an approach to identify newer therapeutic targets. Srivastava S; Krishna S J Stem Cells; 2009; 4(2):123-31. PubMed ID: 20232597 [TBL] [Abstract][Full Text] [Related]
36. Targeting Notch in oncology: the path forward. Majumder S; Crabtree JS; Golde TE; Minter LM; Osborne BA; Miele L Nat Rev Drug Discov; 2021 Feb; 20(2):125-144. PubMed ID: 33293690 [TBL] [Abstract][Full Text] [Related]
37. Synthetic delivery systems for intravenous administration of nucleic acids. Schiffelers RM; de Wolf HK; van Rooy I; Storm G Nanomedicine (Lond); 2007 Apr; 2(2):169-81. PubMed ID: 17716119 [TBL] [Abstract][Full Text] [Related]
38. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Fenske DB; Cullis PR Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372 [TBL] [Abstract][Full Text] [Related]
39. A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Lakkakula JR; Maçedo Krause RW Nanomedicine (Lond); 2014 May; 9(6):877-94. PubMed ID: 24981652 [TBL] [Abstract][Full Text] [Related]
40. Nanomedicine for multimodality treatment of cancer. Mi Y; Guo Y; Feng SS Nanomedicine (Lond); 2012 Dec; 7(12):1791-4. PubMed ID: 23249329 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]